Assessment of the therapeutic impact of Allium sativum against the intestinal and intramuscular stages of murine trichinellosis.

Trichinellosis is a global foodborne zoonotic disease. Numerous drugs used in its treatment exhibit inadequate absorption and diminished efficacy against encysted larvae in muscle tissue. Therefore, there is a need for innovative therapeutic agents to treat trichinellosis. Allium sativum (A. sativum), commonly known as garlic, is a bulbous plant that has been historically utilized in the treatment of various ailments. Currently, there is a paucity of data regarding the in vivo efficacy of A. sativum against trichinellosis. This study assessed the antiparasitic, anti-inflammatory, and antiapoptotic effects of A. sativum in murine models, independently or in conjunction with albendazole (ABZ), against the intestinal and muscular stages of trichinellosis. Fifty mice were equally categorized into five groups: negative control, positive control, ABZ, A. sativum, and a combination of ABZ and A. sativum. The effectiveness of the examined drugs was assessed through parasitological, biochemical, histological, and immunohistochemical methodologies. A. sativum resulted in a significant reduction of adult counts by 39.7% and larval counts by 54.4%. The inflammatory cellular infiltrate in the intestine and muscle was significantly reduced. In mice treated with A. sativum, serum levels of IFN-γ exhibited a significant increase, accompanied by a rise in Bcl-2 expression and a notable decrease in COX-2 expression. In conclusion, A. sativum demonstrates potential as a therapeutic agent for treating experimental trichinellosis, particularly during the muscle phase of the disease. It may serve as a safe promising therapy for trichinellosis.